Home › Drugs by Condition › P › Psoriasis › Efalizumab Pregnancy Warnings
Print Save or Share

Efalizumab Pregnancy and Breastfeeding Warnings

Efalizumab is also known as: Raptiva

Overview

It is not known if Efalizumab can cause harm to the fetus. If you become pregnant while you take Efalizumab or within 6 weeks after you stop it, contact your doctor. You will need to discuss the benefits and risks of using Efalizumab while you are pregnant. It is not known if Efalizumab is found in breast milk. Do not breast-feed while taking Efalizumab.

Efalizumab Pregnancy Warnings

Healthcare providers are encouraged to enroll patients who become pregnant while taking efalizumab (or within six weeks of discontinuing the drug) in the Raptiva pregnancy registry.

Efalizumab has been assigned to pregnancy category C by the FDA. Animal studies have not been performed. There are no controlled data in human pregnancy. Efalizumab should only be given during pregnancy when need has been clearly established.

Efalizumab Breastfeeding Warnings

There are no data on the excretion of efalizumab into human milk. Because maternal immunoglobulins are known to be present in the milk of lactating mothers, and animal data suggest the potential for adverse effects from efalizumab in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

(web5)